Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NextMeds vs OurView Health

NextMeds
Graded #208

Lower grade

vs+1.5
OurView Health
Graded #167

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 66.1/100, but only just.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications. NextMeds is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +21
55
76
Dose & formulationEven
64
64
Clinical oversightOurView Health +2
77
79
Labs & monitoringNextMeds +8
61
53
FulfillmentNextMeds +14
84
70
Contract termsNextMeds +16
61
45
NextMeds · left barOurView Health · right bar

The numbers

MetricNextMedsOurView Health
WeighScore66.1/10067.6/100
GradeCC
Scorecard rank#208#167
Semaglutide$129/mo (plus a separate fee, compounded)$75/mo (starting dose, compounded)
Tirzepatide$179/mo (plus a separate fee, compounded)$135/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NextMeds

Graded #208 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
OurView Health

Graded #167 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • 'Starting at' prices likely require Savings Club membership and/or a longer plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • 'LegitScript Approved' is stated on the site but was not independently verified here
  • Operating medical entity not clearly named (site operated by a marketing agency)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard